- Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2-advanced breast cancer: A phase Ib study.Zhang, Qingyuan; Zhang, Pin; Yan, Min; Yan, Xi; Wang, Xian; Gu, Yuanting; Qu, Xiujuan; Li, Shaorong; Xu, Guoying; Yang, Wenhui; Zhu, Xiaoyu; Zhang, Xiaojing; Xu, BingheAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Dalpiciclib plus fulvestrant in HR+/HER2-advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trialZhang, P.; Zhang, Q. Y.; Hu, X.; Li, W.; Tong, Z.; Sun, T.; Teng, Y.; Wu, X.; Ouyang, Q.; Yan, X.; Cheng, J.; Liu, Q.; Feng, J.; Wang, X.; Xu, G.; Wu, F.; Xia, B.; Xu, B.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 1
- Capivasertib (C) plus fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2e advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohortHu, X.; Zhang, Q.; Sun, T.; Xiong, H.; Li, W.; Teng, Y.; Lu, Y-S.; Tseng, L-M.; Yan, M.; Li, H.; Pang, D.; Chen, S. C.; Chen, W.; Jiang, O.; Wang, J.; Wu, X.; Fan, E.; Jiang, L.; Zeng, X.; Turner, N.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2 ABC
1阅读
